Canadian events cast shadow over Japan's H1N1 vaccine plans
This article was originally published in Scrip
Japan's government is launching a probe into the higher than normal incidence of anaphylaxis reported for one lot of a GlaxoSmithKline H1N1 vaccine in Canada, and may, if necessary, modify its plans to import millions of doses of the product from the UK firm.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.